DOI: 10.36347/sajb.2020.v08i12.002

Pages: 417-422

Background and Aim: Hyperlipidemia is implicated in metabolic diseases like Diabetes mellitus, arteriosclerosis, Hypertension, Obesity, Stroke, Cancer etc. In recent past Methanolic Extract of Moringa oleifera leaves (MEMOL) has gained enormous attention owing to its ameliorative effect in various metabolic diseases. MEMOL has profound hypolipidemic activity due to the presence of Chlorogenic acids (CGA) that causes elimination of lipids [1]. Materials & Methods: Total 90 patients were a part of this study out of which 30 were healthy individuals who were in Control group A. Group B included 30 patients taking Moringa oleifera 500mg BD, Group C included 30 patients taking Moringa (500mgBD)+Atorvastatin (10mgOD). Lipid profile of all of the patients were followed up at the end of 12 weeks and 24 weeks. Lipid profile (Lipid Panel) included LDL, TSC, VLDL & HDL. Results & Conclusion: There was statistical significance in reduction of VLDL at the end of 12 and 24weeks in Group B which might be explained by MEMOL containing CGA. TSC, LDL, HDL changes at the end of 24weeks was statistically significant in Group C. CGA is the bioactive component present in MEMOL which inhibits the action of HMG Co-A reductase and also reduces expression of SREBP1c [2, 3] which attributes to its antihyperlipidemic action.